{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T19:58:19Z","timestamp":1769975899111,"version":"3.49.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2016,7,20]],"date-time":"2016-07-20T00:00:00Z","timestamp":1468972800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100007460","name":"Arvid Nilssons Fond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007460","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003491","name":"Herlev Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005111","name":"Rigshospitalet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005111","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Gangsted Fond (Dk)"},{"DOI":"10.13039\/501100009935","name":"K\u00f8bmand Kristian Kj\u00e6r og hustru Margrethe Kj\u00e6r Fond","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009935","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100008244","name":"Direkt\u00f8r Jacob Madsen og Hustru Olga Madsens Fond","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008244","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100014386","name":"Abbott Diagnostics","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014386","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Tumor Biol."],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1007\/s13277-016-5166-z","type":"journal-article","created":{"date-parts":[[2016,7,20]],"date-time":"2016-07-20T17:58:56Z","timestamp":1469037536000},"page":"12619-12626","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["A novel index for preoperative, non-invasive prediction of macro-radical primary surgery in patients with stage IIIC\u2013IV ovarian cancer\u2014a part of the Danish prospective pelvic mass study"],"prefix":"10.1007","volume":"37","author":[{"given":"Mona Aarenstrup","family":"Karlsen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carsten","family":"Fag\u00f6-Olsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Estrid","family":"H\u00f8gdall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tine Henrichsen","family":"Schnack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ib Jarle","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lotte","family":"Nedergaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lene","family":"Lundvall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magnus Christian","family":"Lydolph","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svend Aage","family":"Engelholm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claus","family":"H\u00f8gdall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,7,20]]},"reference":[{"issue":"2","key":"5166_CR1","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S0090-8258(03)00278-6","volume":"90","author":"SM Eisenkop","year":"2003","unstructured":"Eisenkop SM, Spirtos NM, Friedman RL, Lin WC, Pisani AL, Perticucci S. Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecol Oncol. 2003;90(2):390\u20136.","journal-title":"Gynecol Oncol"},{"issue":"6","key":"5166_CR2","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1002\/cncr.24149.","volume":"115","author":"A Bois du","year":"2009","unstructured":"du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d\u2019Investigateurs Nationaux Pour les Etudes des cancers de l'Ovaire (GINECO). Cancer. 2009;115(6):1234\u201344. doi: 10.1002\/cncr.24149.","journal-title":"Cancer"},{"issue":"10","key":"5166_CR3","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1056\/NEJMoa0908806.","volume":"363","author":"I Vergote","year":"2010","unstructured":"Vergote I, Trope CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363(10):943\u201353. doi: 10.1056\/NEJMoa0908806.","journal-title":"N Engl J Med"},{"issue":"2","key":"5166_CR4","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.ygyno.2013.11.035.","volume":"132","author":"CL Fago-Olsen","year":"2014","unstructured":"Fago-Olsen CL, Ottesen B, Kehlet H, Antonsen SL, Christensen IJ, Markauskas A, et al. Does neoadjuvant chemotherapy impair long-term survival for ovarian cancer patients? A nationwide Danish study. Gynecol Oncol. 2014;132(2):292\u20138. doi: 10.1016\/j.ygyno.2013.11.035.","journal-title":"Gynecol Oncol"},{"issue":"4","key":"5166_CR5","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1159\/000074644","volume":"65","author":"F Fanfani","year":"2003","unstructured":"Fanfani F, Ferrandina G, Corrado G, Fagotti A, Zakut HV, Mancuso S, et al. Impact of interval debulking surgery on clinical outcome in primary unresectable FIGO stage IIIc ovarian cancer patients. Oncology. 2003;65(4):316\u201322.","journal-title":"Oncology"},{"issue":"6","key":"5166_CR6","doi-asserted-by":"publisher","first-page":"477","DOI":"10.3109\/00365513.2014.903430.","volume":"74","author":"N Sandhu","year":"2014","unstructured":"Sandhu N, Karlsen MA, Hogdall C, Laursen IA, Christensen IJ, Hogdall EV. Stability of HE4 and CA125 in blood samples from patients diagnosed with ovarian cancer. Scand J Clin Lab Invest. 2014;74(6):477\u201384. doi: 10.3109\/00365513.2014.903430.","journal-title":"Scand J Clin Lab Invest"},{"issue":"1","key":"5166_CR7","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1006\/gyno.2002.6719","volume":"86","author":"U Saygili","year":"2002","unstructured":"Saygili U, Guclu S, Uslu T, Erten O, Demir N, Onvural A. Can serum CA-125 levels predict the optimal primary cytoreduction in patients with advanced ovarian carcinoma? Gynecol Oncol. 2002;86(1):57\u201361.","journal-title":"Gynecol Oncol"},{"issue":"4","key":"5166_CR8","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1111\/j.1525-1438.2007.01064.x.","volume":"18","author":"AH Arits","year":"2008","unstructured":"Arits AH, Stoot JE, Botterweck AA, Roumen FJ, Voogd AC. Preoperative serum CA125 levels do not predict suboptimal cytoreductive surgery in epithelial ovarian cancer. Int J Gynecol Cancer. 2008;18(4):621\u20138. doi: 10.1111\/j.1525-1438.2007.01064.x.","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"5166_CR9","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/j.1525-1438.2006.00573.x.","volume":"16","author":"TS Barlow","year":"2006","unstructured":"Barlow TS, Przybylski M, Schilder JM, Moore DH, Look KY. The utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer. International journal of gynecological cancer: official journal of the International Gynecological Cancer Society. 2006;16(2):496\u2013500. doi: 10.1111\/j.1525-1438.2006.00573.x.","journal-title":"International journal of gynecological cancer: official journal of the International Gynecological Cancer Society"},{"issue":"1","key":"5166_CR10","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1048-891x.2004.14065.x","volume":"14","author":"EC Brockbank","year":"2004","unstructured":"Brockbank EC, Ind TE, Barton DP, Shepherd JH, Gore ME, A'Hern R, et al. Preoperative predictors of suboptimal primary surgical cytoreduction in women with clinical evidence of advanced primary epithelial ovarian cancer. Int J Gynecol Cancer. 2004;14(1):42\u201350.","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"5166_CR11","first-page":"59","volume":"100","author":"BC Cooper","year":"2002","unstructured":"Cooper BC, Sood AK, Davis CS, Ritchie JM, Sorosky JI, Anderson B, et al. Preoperative CA 125 levels: an independent prognostic factor for epithelial ovarian cancer. Obstet Gynecol. 2002;100(1):59\u201364.","journal-title":"Obstet Gynecol"},{"issue":"2","key":"5166_CR12","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.ygyno.2004.07.045.","volume":"95","author":"GH Eltabbakh","year":"2004","unstructured":"Eltabbakh GH, Mount SL, Beatty B, Simmons-Arnold L, Cooper K, Morgan A. Factors associated with cytoreducibility among women with ovarian carcinoma. Gynecol Oncol. 2004;95(2):377\u201383. doi: 10.1016\/j.ygyno.2004.07.045.","journal-title":"Gynecol Oncol"},{"issue":"9","key":"5166_CR13","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.ejso.2005.05.009.","volume":"31","author":"O Gemer","year":"2005","unstructured":"Gemer O, Lurian M, Gdalevich M, Kapustian V, Piura E, Schneider D, et al. A multicenter study of CA 125 level as a predictor of non-optimal primary cytoreduction of advanced epithelial ovarian cancer. Eur J Surg Oncol. 2005;31(9):1006\u201310. doi: 10.1016\/j.ejso.2005.05.009.","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"5166_CR14","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1046\/j.1525-1438.2003.13019.x","volume":"13","author":"S Memarzadeh","year":"2003","unstructured":"Memarzadeh S, Lee SB, Berek JS, Farias-Eisner R. CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer. 2003;13(2):120\u20134.","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"5166_CR15","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1159\/000076236.","volume":"57","author":"B Obeidat","year":"2004","unstructured":"Obeidat B, Latimer J, Crawford R. Can optimal primary cytoreduction be predicted in advanced stage epithelial ovarian cancer? Role of preoperative serum CA-125 level. Gynecol Obstet Investig. 2004;57(3):153\u20136. doi: 10.1159\/000076236.","journal-title":"Gynecol Obstet Investig"},{"issue":"3","key":"5166_CR16","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.ygyno.2012.11.040.","volume":"128","author":"R Angioli","year":"2013","unstructured":"Angioli R, Plotti F, Capriglione S, Aloisi A, Montera R, Luvero D, et al. Can the preoperative HE4 level predict optimal cytoreduction in patients with advanced ovarian carcinoma? Gynecol Oncol. 2013;128(3):579\u201383. doi: 10.1016\/j.ygyno.2012.11.040.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"5166_CR17","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.ygyno.2012.11.023.","volume":"128","author":"EI Braicu","year":"2013","unstructured":"Braicu EI, Fotopoulou C, Van Gorp T, Richter R, Chekerov R, Hall C, et al. Preoperative HE4 expression in plasma predicts surgical outcome in primary ovarian cancer patients: results from the OVCAD study. Gynecol Oncol. 2013;128(2):245\u201351. doi: 10.1016\/j.ygyno.2012.11.023.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"5166_CR18","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.ygyno.2007.11.002.","volume":"108","author":"S Risum","year":"2008","unstructured":"Risum S, Hogdall C, Loft A, Berthelsen AK, Hogdall E, Nedergaard L, et al. Prediction of suboptimal primary cytoreduction in primary ovarian cancer with combined positron emission tomography\/computed tomography\u2014a prospective study. Gynecol Oncol. 2008;108(2):265\u201370. doi: 10.1016\/j.ygyno.2007.11.002.","journal-title":"Gynecol Oncol"},{"issue":"7","key":"5166_CR19","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1002\/1097-0142(20001001)89:7<1532::AID-CNCR17>3.0.CO;2-A","volume":"89","author":"RE Bristow","year":"2000","unstructured":"Bristow RE, Duska LR, Lambrou NC, Fishman EK, O'Neill MJ, Trimble EL, et al. A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography. Cancer. 2000;89(7):1532\u201340.","journal-title":"Cancer"},{"issue":"7","key":"5166_CR20","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1038\/sj.bjc.6605292.","volume":"101","author":"G Ferrandina","year":"2009","unstructured":"Ferrandina G, Sallustio G, Fagotti A, Vizzielli G, Paglia A, Cucci E, et al. Role of CT scan-based and clinical evaluation in the preoperative prediction of optimal cytoreduction in advanced ovarian cancer: a prospective trial. Br J Cancer. 2009;101(7):1066\u201373. doi: 10.1038\/sj.bjc.6605292.","journal-title":"Br J Cancer"},{"issue":"3","key":"5166_CR21","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.tjog.2013.10.041.","volume":"53","author":"HJ Kim","year":"2014","unstructured":"Kim HJ, Choi CH, Lee YY, Kim TJ, Lee JW, Bae DS, et al. Surgical outcome prediction in patients with advanced ovarian cancer using computed tomography scans and intraoperative findings. Taiwan J Obstet Gynecol. 2014;53(3):343\u20137. doi: 10.1016\/j.tjog.2013.10.041.","journal-title":"Taiwan J Obstet Gynecol"},{"issue":"5","key":"5166_CR22","doi-asserted-by":"publisher","first-page":"424","DOI":"10.3109\/01443615.2014.899330.","volume":"34","author":"ML MacKintosh","year":"2014","unstructured":"MacKintosh ML, Rahim R, Rajashanker B, Swindell R, Kirmani BH, Hunt J, et al. CT scan does not predict optimal debulking in stage III-IV epithelial ovarian cancer: a multicentre validation study. J Obstet Gynaecol. 2014;34(5):424\u20138. doi: 10.3109\/01443615.2014.899330.","journal-title":"J Obstet Gynaecol"},{"issue":"2","key":"5166_CR23","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.ygyno.2007.11.004.","volume":"108","author":"R Salani","year":"2008","unstructured":"Salani R, Axtell A, Gerardi M, Holschneider C, Bristow RE. Limited utility of conventional criteria for predicting unresectable disease in patients with advanced stage epithelial ovarian cancer. Gynecol Oncol. 2008;108(2):271\u20135. doi: 10.1016\/j.ygyno.2007.11.004.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"5166_CR24","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.ygyno.2005.09.060.","volume":"100","author":"R Angioli","year":"2006","unstructured":"Angioli R, Palaia I, Zullo MA, Muzii L, Manci N, Calcagno M, et al. Diagnostic open laparoscopy in the management of advanced ovarian cancer. Gynecol Oncol. 2006;100(3):455\u201361. doi: 10.1016\/j.ygyno.2005.09.060.","journal-title":"Gynecol Oncol"},{"key":"5166_CR25","unstructured":"Danish Cancer Biobank [database on the Internet]. 2012. www.cancerbiobank.dk . Accessed 22 Apr 2016."},{"issue":"3","key":"5166_CR26","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1097\/IGC.0000000000000368.","volume":"25","author":"MJ Rutten","year":"2015","unstructured":"Rutten MJ, van de Vrie R, Bruining A, Spijkerboer AM, Mol BW, Kenter GG, et al. Predicting surgical outcome in patients with International Federation of Gynecology and Obstetrics stage III or IV ovarian cancer using computed tomography: a systematic review of prediction models. Int J Gynecol Cancer. 2015;25(3):407\u201315. doi: 10.1097\/IGC.0000000000000368.","journal-title":"Int J Gynecol Cancer"},{"key":"5166_CR27","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-14-0447.","author":"NS Karlsen","year":"2014","unstructured":"Karlsen NS, Karlsen MA, Hogdall CK, Hogdall E. HE4 tissue expression and serum HE4 levels in healthy individuals and patients with benign or malignant tumours\u2014a systematic review. Cancer Epidemiol Biomark Prev. 2014. doi: 10.1158\/1055-9965.EPI-14-0447.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"5166_CR28","doi-asserted-by":"publisher","first-page":"CD009786","DOI":"10.1002\/14651858.CD009786.pub2.","volume":"2","author":"MJ Rutten","year":"2014","unstructured":"Rutten MJ, Leeflang MM, Kenter GG, Mol BW, Buist M. Laparoscopy for diagnosing resectability of disease in patients with advanced ovarian cancer. Cochrane Database Syst Rev. 2014;2:CD009786. doi: 10.1002\/14651858.CD009786.pub2.","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Tumor Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-016-5166-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13277-016-5166-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-016-5166-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T01:43:52Z","timestamp":1589679832000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13277-016-5166-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,20]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["5166"],"URL":"https:\/\/doi.org\/10.1007\/s13277-016-5166-z","relation":{},"ISSN":["1010-4283","1423-0380"],"issn-type":[{"value":"1010-4283","type":"print"},{"value":"1423-0380","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,20]]}}}